{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:47:54Z","timestamp":1791276474612,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1097\/ftd.0b013e31820530cd","type":"journal-article","created":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T12:25:36Z","timestamp":1293798336000},"page":"86-93","source":"Crossref","is-referenced-by-count":61,"title":["Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"33","author":[{"given":"Arwa","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Dieter","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Czock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FTD.0b013e318167d0e0","article-title":"Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.","volume":"30","author":"Smith","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome p450 enzymes involved in the N-oxidation of voriconazole.","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R4-14-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R5-14-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications.","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-14-20210129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/00912700222011445","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.","volume":"42","author":"Lazarus","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clpt.2005.01.024","article-title":"Opposite effects of short-term and long-term St Johns Wort intake on voriconazole pharmacokinetics.","volume":"78","author":"Rengelshausen","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R10-14-20210129","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1128\/AAC.00579-07","article-title":"Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications.","volume":"51","author":"Geist","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1128\/AAC.00805-08","article-title":"Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with CNS aspergillosis.","volume":"52","author":"Hafner","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0091270008327537","article-title":"CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.","volume":"49","author":"Weiss","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.clpt.6100291","article-title":"Impact of the ultrarapid CYP2C19*17 a17 allele on serum concentration of escitalopram in psychiatric patients.","volume":"83","author":"Rudberg","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/bjc.1995.450","article-title":"Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?","volume":"72","author":"Lennard","year":"1995","journal-title":"Br J Cancer"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0002-8703(83)90006-6","article-title":"Amiodarone pharmacokinetics.","volume":"106","author":"Holt","year":"1983","journal-title":"Am Heart J"},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"R18-14-20210129","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","article-title":"Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.","volume":"68","author":"Scholz","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1128\/AAC.47.7.2348-2350.2003","article-title":"Development and validation of a high-performance liquid chromatography assay for voriconazole.","volume":"47","author":"Pennick","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/AAC.01540-09","article-title":"Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodialfiltration.","volume":"54","author":"Hafner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-14-20210129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0378-4347(96)00408-2","article-title":"Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column.","volume":"691","author":"Stopher","year":"1997","journal-title":"Chromatogr B Biomed Sci Appl"},{"key":"R22-14-20210129","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2125.2008.03104.x","article-title":"Increased omeprazole metabolism in carriers of the CYP2C19*17 alle17 allele; a pharmacokinetic study in healthy volunteers.","volume":"65","author":"Baldwin","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children.","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R24-14-20210129","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijantimicag.2006.01.003","article-title":"Clinical pharmacokinetics of voriconazole.","volume":"27","author":"Leveque","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"R25-14-20210129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel.","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"R27-14-20210129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3810\/pgm.2010.01.2112","article-title":"Review of medication adherence in children and adults with ADHD.","volume":"122","author":"Adler","year":"2010","journal-title":"Postgrad Med"},{"key":"R28-14-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jpepsy\/jsp054","article-title":"Medical adherence in young adolescents with spina bifida: longitudinal associations with family functioning.","volume":"35","author":"Stepansky","year":"2010","journal-title":"J Pediatr Psychol"},{"key":"R29-14-20210129","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jpepsy\/15.4.437","article-title":"Adherence issues in the medical management of asthma.","volume":"15","author":"Lemanek","year":"1990","journal-title":"J Pediatr Psychol"},{"key":"R30-14-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","article-title":"Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin 17.","volume":"69","author":"Li-Wan-Po","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R31-14-20210129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":"A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.","volume":"79","author":"Sim","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R32-14-20210129","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole.","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e31820530cd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:47:18Z","timestamp":1786042038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201102000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31820530cd","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}